US 12,109,184 B2
Personalized methods of treating cancer
Oliver D.K. Maddocks, Glasgow (GB)
Assigned to Faeth Therapeutics, Inc., Austin, TX (US); and Cancer Research Technology Limited, London (GB)
Filed by CANCER RESEARCH TECHNOLOGY LIMITED, London (GB); and Faeth Therapeutics, Inc., Austin, TX (US)
Filed on Jun. 3, 2021, as Appl. No. 17/338,283.
Claims priority of provisional application 63/034,679, filed on Jun. 4, 2020.
Prior Publication US 2022/0054444 A1, Feb. 24, 2022
Int. Cl. A61K 31/198 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/198 (2013.01) [A61P 35/00 (2018.01)] 19 Claims
 
1. A method for treating a cancer having dysregulated polyamine metabolism in a subject in need thereof, wherein the cancer having dysregulated polyamine metabolism is breast cancer, colorectal cancer, pancreatic cancer, or brain cancer, the method comprising administering to the subject a therapeutically effective amount of a dietary product, wherein:
the dietary product comprises at most about 0.5% (w/w) of cysteine or cystine; the dietary product comprises at least about 7.5% (w/w) of methionine;
the therapeutically effective amount of the dietary product is from about 0.5 g/kg/day to about 1 g/kg/day; and
the subject is undergoing a cancer therapy for the cancer having dysregulated polyamine metabolism.